News and Trends 20 Jun 2018 Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […] June 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Gates Foundation and Oxitec Fight Malaria with Genetically-Modified Mosquitoes The Bill & Melinda Gates Foundation has partnered with Oxitec for the development of a new strain of genetically-modified mosquitoes that can help reduce the spread of malaria in America. In its latest effort to free the world of malaria, the Bill & Melinda Gates Foundation has joined forces with Oxitec, a British company that […] June 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2018 A Chip Could Help Us Identify Wheeze-Causing Types of Viruses Researchers in Vienna have developed a chip that identifies cold viruses that cause flare-ups of respiratory conditions such as asthma. The technology could help identify culprit viruses and help those affected take the best preventive and treatment measures. The chip, created by researchers at the Medical University of Vienna, uses a small blood sample to […] June 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2018 Biomaterial to Regenerate Teeth Approved in Europe The Israeli company Datum Dental has received approval to launch a biomaterial for dental implants in Europe and Canada. Datum Dental has developed a biomaterial specifically designed to help the body regenerate real bone tissue after dental operations. Launched in the US last year, the biomaterial has now received CE marking in Europe and approval […] June 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2018 London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […] June 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Device Helps Protect Cereals by Diagnosing Herbicide Resistance in Weeds Mologic and Newcastle University have launched a diagnostic device that provides rapid information on herbicide resistance for a common weed, which could help cut major losses for the British agricultural industry. The partnership between academia and industry has developed a device that can diagnose herbicide resistance in the blackgrass weed, which could help farmers protect […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 French Biotech Develops a New Generation of Safer CAR-T Cells Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells. Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the […] June 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 Placenta Cell Therapy Improves Mobility in Patients with Peripheral Artery Disease The Israeli biotech Pluristem has Phase II data indicating that its cell therapy made of placenta cells can help patients suffering from peripheral artery disease recover their mobility. The trial, run in the US, Germany, South Korea and Israel, enrolled 172 patients with intermittent claudication, an early stage of peripheral artery disease where the legs […] June 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2018 Spider Silk Shows Promise in Vaccine Field Swiss and German scientists have engineered spider-silk microparticles that can be used to protect a vaccine particle, allow it to enter immune cells and trigger T-cell immunity without toxic effects. The team, partnered by AMSilk — the German biotech behind Adidas’ biodegradable shoes, hopes their technique will allow more targeted and stable vaccines against difficult targets […] June 12, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2018 Scientists Warn CRISPR Therapy Could Cause Cancer as First Human Trials Take Place A study at Karolinska Institutet in Sweden has revealed that CRISPR-Cas9 gene editing could favor mutations in the most common cancer-causing gene. What does it mean for the first CRISPR therapy trials in humans? CRISPR-Cas9 has taken the life sciences field by storm, making gene editing simpler and faster than ever. Although CRISPR-Cas9 gene […] June 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2018 Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder Saniona, a biotech focused on ion channel research, plans to test its lead candidate in a Phase IIa study for the rare eating disorder hypothalamic obesity. Saniona, based in Copenhagen, plans to start a Phase IIa trial testing its product, Tesomet, a combination of tesofensine and metoprolol, in hypothalamic obesity. The study would complement the […] June 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email